📈 Growth Hormone Peptides

A growth hormone releasing hormone (GHRH) analog most commonly stacked with Ipamorelin to stimulate natural GH pulsatile release without disrupting the hypothalamic axis.

Dose: 100–300 mcg before bed (subcutaneous)

A selective growth hormone secretagogue that triggers GH release from the pituitary without significantly raising cortisol or prolactin. The safest GH peptide with the fewest side effects.

Dose: 100–300 mcg before bed (subcutaneous)

An FDA-approved GHRH analog that stimulates natural growth hormone production. Clinically proven to reduce visceral adipose tissue and increasingly used off-label for body recomposition.

Dose: 2 mg daily (subcutaneous)

The original synthetic GHRH(1–29) and the most accessible GH-stimulating peptide for age-related hormone decline. Stimulates the body's own pulsatile GH release rather than replacing it.

Dose: 200–500 mcg before bed (subcutaneous)

An orally active ghrelin-receptor agonist that drives 24-hour increases in GH and IGF-1. Technically a non-peptide small molecule but always grouped with GH peptides.

Dose: 10–25 mg orally, once daily

A potent synthetic ghrelin-mimetic GH secretagogue. Drives strong GH spikes but raises cortisol and prolactin more than newer alternatives like Ipamorelin.

Dose: 100–300 mcg, 1–3 times daily (subcutaneous)

An older GHS that produces strong appetite stimulation in addition to GH release. Largely supplanted by Ipamorelin and GHRP-2 for clinical use but still common in research stacks.

Dose: 100–300 mcg, 1–3 times daily (subcutaneous)

The strongest GH-releasing hexapeptide and one of the few peptides with documented direct cardiac benefits in animal models. Tachyphylaxis (diminished response over time) limits long-term use.

Dose: 100 mcg, 1–2 times daily (subcutaneous)

The full 44-amino-acid GHRH sequence. The natural pituitary stimulus for GH release. Largely supplanted in clinical use by sermorelin/tesamorelin but remains a research and diagnostic tool.

Dose: 1 mcg/kg IV (diagnostic test)